Evidence map›Paper›PMID 33628037›Full record

ArticleInfection and drug resistance2021

Longitudinal Study of the Drug Resistance in

Na Pei, Qingxia Liu, Xinyi Cheng, Tianzhu Liang, Zijuan Jian, Siyi Wang, Yiming Zhong, Jingxuan He, Mao Zhou, Karsten Kristiansen and 3 more

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Resistance Pattern ofMedicina (Kaunas, Lithuania) · 2024
    Article
  4. Monitoring Multi-Drug ResistantInfection and drug resistance · 2024
    Article
  5. Article
  6. Article
  7. Prevalence and Antibiogram Pattern ofAntibiotics (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Na Pei *BGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Qingxia Liu *Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Xinyi Cheng *BGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Tianzhu LiangBGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Zijuan JianDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Siyi WangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Yiming ZhongDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Jingxuan HeDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Mao ZhouDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Karsten KristiansenBGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Weijun ChenBGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Wenen LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Junhua LiBGI-Shenzhen, Shenzhen, 518083, People's Republic of China.ORCID 0000-0001-6784-1873
Central South University · CNBGI Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMulti-drug resistant

methodsAll the KP clinical isolates were retrospectively collected from a tertiary hospital in Hunan province of China from Jan 5, 2013 to Jul 24, 2018. All the isolates were identified by MALDI-TOF MS analysis. Twenty-four antimicrobial agents were tested by antimicrobial susceptibility testing. Fisher exact test and logistic regression were used to analyze the association between clinical factors and antimicrobial non-susceptibility for seven second-choice antimicrobials.

resultsA total of 4128 KP isolates were collected in our study. The non-susceptible rates (NSRs) to ertapenem, imipenem and tigecycline increased considerably from 2013 to 2018 (13.6% to 28.6%, 10.1% to 28.9%, 10.8% to 46.5%, respectively). Amikacin presents the lowest NSR among 3 aminoglycosides (3.8-22.8%). The multi-drug NSRs among KP isolates to second-choice antimicrobials (88.6-100%) were higher than to all drugs (68.0%). The NSRs varied significantly among departments and sample sources. Higher ETP/IPM/AK NSRs (39.8/39.7/30.6%) were observed in Intensive Care Unit, and ETP/IPM non-susceptible isolates tended to distribute in cerebrospinal fluid. From 2015 to 2017, the NSRs of ETP, IPM, and AK showed an opposite trend of seasonal fluctuations to SXT.

conclusionHigher multi-drug resistance (MDR) rates were observed in KP isolates to second-choice antimicrobials than to others, among which MDR rates to carbapenems or AK are the highest. A unique pattern of MIC and time distributions of MDR were observed. Clinical factors including gender were correlated with MDR rates of KP. Isolates in ICU and CSF showed higher NSRs in carbapenems which should be paid more attention to, and temporal distribution of NSRs was observed.

Indexed as

drug resistanceKlebsiella pneumoniaeNSRphenotypic epidemiology

Identifiers

PMID33628037
PMCPMC7898056
OpenAlexW3131162007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.